Press releases
- Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
- Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
- Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer
- Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting
- Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
- Carisma Therapeutics to Present at Upcoming Conferences
- Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Carisma Therapeutics Announces Changes to its Board of Directors
More ▼
Key statistics
On Wednesday, Carisma Therapeutics Inc (W2J:STU) closed at 1.30, 6.64% above its 52-week low of 1.22, set on May 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.27 |
---|---|
High | 1.31 |
Low | 1.27 |
Bid | 1.27 |
Offer | 1.38 |
Previous close | 1.26 |
Average volume | 0.00 |
---|---|
Shares outstanding | 41.54m |
Free float | 28.18m |
P/E (TTM) | -- |
Market cap | 58.99m USD |
EPS (TTM) | -2.01 USD |
Data delayed at least 15 minutes, as of May 22 2024.
More ▼